ATE511655T1 - Verfahren zur auswertung eines myelounterdrückungszustands - Google Patents

Verfahren zur auswertung eines myelounterdrückungszustands

Info

Publication number
ATE511655T1
ATE511655T1 AT03737046T AT03737046T ATE511655T1 AT E511655 T1 ATE511655 T1 AT E511655T1 AT 03737046 T AT03737046 T AT 03737046T AT 03737046 T AT03737046 T AT 03737046T AT E511655 T1 ATE511655 T1 AT E511655T1
Authority
AT
Austria
Prior art keywords
patient
evaluation
methods
suppression condition
myelosuppressive
Prior art date
Application number
AT03737046T
Other languages
English (en)
Inventor
Rosalyn Blumenthal
David Goldenberg
Original Assignee
Ct For Molecular Medicine And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct For Molecular Medicine And Immunology filed Critical Ct For Molecular Medicine And Immunology
Application granted granted Critical
Publication of ATE511655T1 publication Critical patent/ATE511655T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03737046T 2002-06-14 2003-06-13 Verfahren zur auswertung eines myelounterdrückungszustands ATE511655T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/173,550 US7112409B2 (en) 1999-01-29 2002-06-14 Method of determining cytokine dosage for myelosuppressive state
PCT/US2003/018601 WO2003106967A2 (en) 2002-06-14 2003-06-13 Method of evaluating myelosuppressive state

Publications (1)

Publication Number Publication Date
ATE511655T1 true ATE511655T1 (de) 2011-06-15

Family

ID=29733378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737046T ATE511655T1 (de) 2002-06-14 2003-06-13 Verfahren zur auswertung eines myelounterdrückungszustands

Country Status (7)

Country Link
US (3) US7112409B2 (de)
EP (1) EP1585963B1 (de)
JP (1) JP2006501171A (de)
AT (1) ATE511655T1 (de)
AU (1) AU2003238023A1 (de)
CA (1) CA2489444A1 (de)
WO (1) WO2003106967A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112409B2 (en) * 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
US8315810B2 (en) * 2006-11-10 2012-11-20 Koninklijke Philips Electronics N.V. Apparatus, method, computer-readable medium, and use for therapy planning in treatment of a patient
US20130022501A1 (en) * 2007-09-14 2013-01-24 University Of Medicine And Dentistry Of New Jersey Salivary Bioassay for Early Detection of Bone Loss
EP2310006A4 (de) * 2008-07-03 2012-04-25 Mayo Foundation Krebsbehandlung
US10853819B2 (en) 2011-04-14 2020-12-01 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US10445846B2 (en) 2011-04-14 2019-10-15 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
US8514067B2 (en) 2011-08-16 2013-08-20 Elwha Llc Systematic distillation of status data relating to regimen compliance
CN103827667B (zh) * 2011-09-13 2016-07-13 巴斯夫欧洲公司 评估造血毒性的工具和方法
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
US10340034B2 (en) 2011-12-30 2019-07-02 Elwha Llc Evidence-based healthcare information management protocols
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
US10402927B2 (en) 2011-12-30 2019-09-03 Elwha Llc Evidence-based healthcare information management protocols
WO2013155129A1 (en) * 2012-04-11 2013-10-17 Indiana University Research And Technology Corporation System and method for concurrent chemotherapy and radiotherapy cancer treatment, and chemotherapeutic agent detection strategy
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
EP3154586B1 (de) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Behandlung von lymphomen
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432926A4 (de) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Verfahren zur verminderung der toxizität eines chemotherapeutikums
EP3432928A4 (de) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Verfahren zur verbesserung des therapeutischen index für ein chemotherapeutikum
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
RU2021128415A (ru) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (de) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Verfahren zur behandlung von dreifach negativem brustkrebs unter verwendung von zusammensetzungen aus antikörpern und trägerproteinen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
IT1249708B (it) 1991-09-23 1995-03-09 Tecnogen Scpa Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva.
CA2089304A1 (en) 1992-02-20 1993-08-21 Linda Anderson-Mauser Diagnosis of candida vaginitis by detecting d-arabinitol in vaginal fluid
ES2150495T5 (es) 1993-05-19 2007-02-16 Schering Corporation Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE69626829T2 (de) 1995-08-04 2004-03-18 Lek Farmacevtska Druzba D.D. Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
US7112409B2 (en) 1999-01-29 2006-09-26 Center For Molecular Medicine And Immunology Method of determining cytokine dosage for myelosuppressive state
US6649352B1 (en) 1999-01-29 2003-11-18 Center For Molecular Medicine And Immunology Method of evaluating myelosuppressive state
US7163671B2 (en) * 2000-02-29 2007-01-16 Chugai Seiyaku Kabushiki Kaisha Long-term stabilized formulations

Also Published As

Publication number Publication date
US20060193770A1 (en) 2006-08-31
JP2006501171A (ja) 2006-01-12
EP1585963A4 (de) 2006-11-29
WO2003106967A2 (en) 2003-12-24
US20070036749A1 (en) 2007-02-15
EP1585963A2 (de) 2005-10-19
US20060088891A1 (en) 2006-04-27
AU2003238023A1 (en) 2003-12-31
EP1585963B1 (de) 2011-06-01
US7465551B2 (en) 2008-12-16
WO2003106967A3 (en) 2005-11-17
WO2003106967A9 (en) 2004-02-26
CA2489444A1 (en) 2003-12-24
US7112409B2 (en) 2006-09-26
US7279289B2 (en) 2007-10-09

Similar Documents

Publication Publication Date Title
ATE511655T1 (de) Verfahren zur auswertung eines myelounterdrückungszustands
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
AU8116301A (en) Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
EP1712239A3 (de) Interleukin-1 Inhibitoren zur Behandlung von Erkrankungen
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE556711T1 (de) Verfahren zur verbesserung der hautqualität
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
NO20072055L (no) Fremgangsmater og sammensetninger for behandling av flaviviruser, pestiviruser og hepacivirus
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
TW200606162A (en) Pyrazolopyridine derivatives
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
AU4258101A (en) Combination therapies with vascular damaging activity
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
TW200611693A (en) GPR35 and modulators thereof for the treatment of metabolic-related disorders
NO20055449L (no) Fremgangsmate for diagnostisering av behandling av kreft
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties